Soluble elastin fragments in serum are elevated in acute aortic dissection

Area of Science:

• Biochemistry
• Medical Diagnostics
• Cardiovascular Research

Background:

• Acute aortic dissection (AAD) is a life-threatening condition requiring rapid diagnosis.
• Current diagnostic methods can be invasive or delayed.
• Biomarkers for early and accurate detection of AAD are needed.

Purpose of the Study:

• To develop an enzyme-linked immunosorbent assay (ELISA) for quantifying soluble elastin fragments (sELAF) in serum.
• To evaluate the diagnostic utility of sELAF for acute aortic dissection (AAD).
• To assess the potential of sELAF in differentiating AAD from acute myocardial infarction (AMI).

Main Methods:

• Developed a novel ELISA using double monoclonal antibodies specific to human aortic elastin.
• Measured sELAF levels in serum samples from 25 AAD patients, 50 AMI patients, and 474 healthy individuals.
• Analyzed sELAF levels in relation to age, disease status, and pseudolumen status in AAD.

Main Results:

• The developed ELISA demonstrated measurable sELAF levels, which increased with age in healthy subjects.
• A positivity cutoff (mean+3 SD) identified 64.0% of AAD patients versus 2.0% of AMI patients.
• AAD patients with open pseudolumen showed significantly higher sELAF levels compared to those with thrombotic closure (P<0.005).

Conclusions:

• Serum sELAF levels, measured by the novel ELISA, show potential as a diagnostic and screening marker for AAD.
• sELAF may aid in distinguishing AAD from AMI, improving diagnostic accuracy.
• Further validation is warranted to establish sELAF as a clinical tool for AAD management.